簡介

本頁面提供了有關 Michael Narachi 已知的內部交易歷史的全面分析。內部人士包括公司的高管、董事或重要投資者。一般而言,基於內幕、非公開信息進行交易是非法的。這並不意味著他們在自己的公司進行任何交易都是非法的。但是,他們必須透過Form 4向美國證券交易委員會(SEC)報告所有交易。盡管存在這些限制,學術研究表明,內部人士 - 整體而言 - 在自己公司中的投資表現往往優於市場。

平均交易盈利能力

「平均交易盈利能力」衡量了內部人士在過去三年中所有非計劃性的公開市場購買交易的平均回報率。計算過程包括檢查每筆交易,排除了作為10b5-1交易計劃的一部分的交易。然後,對每筆交易在3、6和12個月的表現進行平均,以生成該筆交易最終的表現指標。最終,將所有交易的表現指標進行平均,計算出內部人士的總體平均表現指標。列表僅包含在過去兩年中進行過至少三筆交易的內部人士。

如果內部人士的交易盈利能力顯示為"N/A",則可能是因為該內部人士在過去三年內沒有進行任何公開市場購買交易,或者他們進行的交易距離現在太近,無法計算出可靠的表現指標。

更新頻率:每日

查看收益最高的的內幕交易者列表。

報告內部持倉的公司

SEC文件顯示Michael Narachi已報告在以下公司擁有持倉或進行了交易:

證券 職位 最新報告的持倉
US:RARE / Ultragenyx Pharmaceutical Inc. Director 40,441
US:OREX / Orexigen Therapeutics, Inc. CEO & President, Director 252,000
US:CLDN / Celladon Corp Director 50,000
US:US00163UAD81 / AMAG Pharmaceuticals, Inc. Bond Director 7,600
如何解讀這些圖表

以下圖表顯示了在Michael Narachi進行的每筆公開市場非計劃交易後證券的股價表現。非計劃交易是指沒有作為10b5-1交易計劃的一部分而進行的交易。股價表現以累積百分比變化的方式繪製。例如,如果一筆內部人士交易是在2019年1月1日進行的,該圖表將顯示該證券的每日百分比變化直至當前日期。如果在此期間股價從10美元漲至15美元,則股價的累積百分比變化將為50%。從10美元漲至20美元的價格變化將為100%,而從10美元跌至5美元的價格變化將為-50%。

最終,我們將評估內部人士的交易與股價的超額回報(正向或負向)之間的相關性,以判斷內部人士是否在交易中利用內部信息獲利。如果內部人士有這樣的行為,我們預期看到(a)購買後的正回報,或者(b)賣出後的負回報。對於情況(a),購買圖表將顯示一系列向上傾斜的曲線,表示每次購買後都有正回報。對於情況(b),賣出圖表將顯示一系列向下傾斜的曲線,表示每次賣出後都有負回報。

然而,僅憑這一點還不足以得出結論。例如,如果公司的股價在多年內呈現非周期性上升,我們會預期所有購買後的圖表都呈現向上傾斜。同樣地,多年來呈現非周期性下降的股價會導致賣出後的圖表也呈現向下傾斜。這兩種情況的圖表都不能表示內部人士在進行內幕交易。

最有力的指標是在公司股價呈極度循環波動的情況下,「購買」圖表顯示正向信號,而「賣出」圖表顯示負向趨勢。這種情況強烈暗示內部人士可能根據內幕信息精確地計時進行交易,以獲得財務優勢。

歷史內部人交易

該表格顯示了由 Michael Narachi 進行的所有內幕交易的完整列表,這些交易已向美國證券交易委員會(SEC)披露。

呈報日期 交易日期 表格 證券代碼 證券 代碼 10b5-1 股份 剩餘股份 %
變化
每股
股價
交易
金額
剩餘
金額
2026-05-18 2026-05-14 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 7,751 40,441 23.71
2025-05-19 2025-05-15 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 5,740 32,690 21.30
2024-06-20 2024-06-18 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 5,345 26,950 24.74
2023-06-09 2023-06-07 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 3,860 21,605 21.75
2022-06-28 2022-06-24 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 3,300 17,745 22.85
2021-06-28 2021-06-24 4 RARE Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy)
A - Award 4,125 4,125
2021-06-28 2021-06-24 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 2,145 14,445 17.44
2020-06-30 2020-06-26 4 RARE Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy)
A - Award 4,250 4,250
2020-06-30 2020-06-26 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 2,550 12,300 26.15
2019-06-13 2019-06-11 4 RARE Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy)
A - Award 5,000 5,000
2019-06-13 2019-06-11 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 3,000 9,750 44.44
2018-06-20 2018-06-19 4 RARE Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy)
A - Award 5,000 5,000
2018-06-20 2018-06-19 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 3,000 6,750 80.00
2017-10-17 2017-10-13 4 OREX Orexigen Therapeutics, Inc.
Restricted Stock Unit (RSU)
A - Award 252,000 252,000
2017-06-22 2017-06-22 4 RARE Ultragenyx Pharmaceutical Inc.
Employee Stock Option (Right to Buy)
A - Award 3,750 3,750
2017-06-22 2017-06-22 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 1,875 3,750 100.00
2017-06-02 2017-05-31 4 OREX Orexigen Therapeutics, Inc.
Common Stock
A - Award 626 8,356 8.10 1.55 970 12,952
2017-02-07 2017-02-03 4 OREX Orexigen Therapeutics, Inc.
Stock Option
A - Award 157,500 157,500
2017-02-07 2017-02-03 4 OREX Orexigen Therapeutics, Inc.
Stock Option
A - Award 315,000 315,000
2016-12-02 2016-11-30 4 OREX Orexigen Therapeutics, Inc.
Common Stock
A - Award 802 6,312 14.56 1.67 1,339 10,541
2016-07-14 2016-07-12 4 OREX Orexigen Therapeutics, Inc.
Stock Option
A - Award 63,000 63,000
2016-07-14 2016-07-12 4 OREX Orexigen Therapeutics, Inc.
Stock Option
A - Award 315,000 315,000
2016-07-14 2016-07-12 4 OREX Orexigen Therapeutics, Inc.
Stock Option
A - Award 105,000 105,000
2016-07-14 2016-07-12 4 OREX Orexigen Therapeutics, Inc.
Stock Option
A - Award 525,000 525,000
2016-06-14 2016-06-09 4 RARE Ultragenyx Pharmaceutical Inc.
Employee Stock Option (Right to Buy)
A - Award 3,750 3,750
2016-06-14 2016-06-09 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 1,875 1,875
2016-06-02 2016-05-31 4 OREX Orexigen Therapeutics, Inc.
Common Stock
A - Award 8,777 69,285 14.51 0.34 2,984 23,557
2016-02-04 2016-02-02 4 OREX Orexigen Therapeutics, Inc.
Performance Stock Units
A - Award 800,000 800,000
2016-02-04 2016-02-02 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
A - Award 700,000 700,000
2016-02-04 2015-11-30 4 OREX Orexigen Therapeutics, Inc.
Common Stock
A - Award 1,761 60,508 3.00 2.03 3,575 122,831
2016-02-04 2015-05-29 4 OREX Orexigen Therapeutics, Inc.
Common Stock
A - Award 721 58,747 1.24 4.17 3,007 244,975
2015-06-22 2015-06-18 4 RARE Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy)
A - Award 7,500 7,500
2015-06-05 2015-06-04 4 CLDN Celladon Corp
Stock option (right to buy)
A - Award 10,000 50,000 25.00
2015-02-24 2015-02-20 4 RARE Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy)
A - Award 17,500 17,500
2015-02-05 2015-02-03 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
A - Award 635,150 635,150
2014-09-15 2014-09-15 4 OREX Orexigen Therapeutics, Inc.
Common Stock
P - Purchase 50,000 58,026 622.98 4.78 239,100 277,480
2014-05-21 2014-05-20 4 CLDN Celladon Corp
Stock option (right to buy)
A - Award 10,000 10,000
2014-02-11 2014-02-07 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
A - Award 673,500 673,500
2014-02-11 2013-11-29 4 OREX Orexigen Therapeutics, Inc.
Common Stock
A - Award 3,980 3,980 5.34 21,253 21,253
2014-02-06 2014-02-04 4 CLDN Celladon Corp
Common Stock
P - Purchase 62,500 62,500 8.00 500,000 500,000
2013-05-24 2013-05-23 4 AMAG AMAG PHARMACEUTICALS INC.
Stock Option (Right to Buy)
A - Award 7,600 7,600
2013-05-24 2013-05-23 4 AMAG AMAG PHARMACEUTICALS INC.
Common Stock
A - Award 3,800 23,900 18.91
2013-02-19 2013-02-15 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
A - Award 555,000 555,000
2012-07-19 2012-07-17 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
M - Exercise -25,762 1,774,238 -1.43
2012-07-19 2012-07-17 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
M - Exercise -124,238 1,761,562 -6.59
2012-07-19 2012-07-17 4 OREX Orexigen Therapeutics, Inc.
Common Stock
S - Sale X -25,762 0 -100.00 7.66 -197,337
2012-07-19 2012-07-17 4 OREX Orexigen Therapeutics, Inc.
Common Stock
M - Exercise X 25,762 25,762 1.70 43,795 43,795
2012-07-19 2012-07-17 4 OREX Orexigen Therapeutics, Inc.
Common Stock
S - Sale X -124,238 0 -100.00 7.66 -951,663
2012-07-19 2012-07-17 4 OREX Orexigen Therapeutics, Inc.
Common Stock
M - Exercise X 124,238 124,238 1.66 206,235 206,235
2012-07-13 2012-07-13 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
M - Exercise -147,100 1,885,800 -7.24
2012-07-13 2012-07-13 4 OREX Orexigen Therapeutics, Inc.
Common Stock
S - Sale X -147,100 0 -100.00 6.70 -985,570
2012-07-13 2012-07-13 4 OREX Orexigen Therapeutics, Inc.
Common Stock
M - Exercise X 147,100 147,100 1.66 244,186 244,186
2012-07-13 2012-07-12 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
M - Exercise -2,900 2,032,900 -0.14
2012-07-13 2012-07-12 4 OREX Orexigen Therapeutics, Inc.
Common Stock
S - Sale X -2,900 0 -100.00 6.66 -19,314
2012-07-13 2012-07-12 4 OREX Orexigen Therapeutics, Inc.
Common Stock
M - Exercise X 2,900 2,900 1.66 4,814 4,814
2012-06-29 2012-06-29 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
M - Exercise -125,000 2,035,800 -5.78
2012-06-29 2012-06-29 4 OREX Orexigen Therapeutics, Inc.
Common Stock
S - Sale X -125,000 0 -100.00 6.08 -760,000
2012-06-29 2012-06-29 4 OREX Orexigen Therapeutics, Inc.
Common Stock
M - Exercise X 125,000 125,000 1.66 207,500 207,500
2012-06-29 2012-06-28 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
M - Exercise -100,000 2,160,800 -4.42
2012-06-29 2012-06-28 4 OREX Orexigen Therapeutics, Inc.
Common Stock
S - Sale X -100,000 0 -100.00 5.66 -566,000
2012-06-29 2012-06-28 4 OREX Orexigen Therapeutics, Inc.
Common Stock
M - Exercise X 100,000 100,000 1.66 166,000 166,000
2012-05-29 2012-05-25 4 AMAG AMAG PHARMACEUTICALS INC.
Common Stock
P - Purchase 5,500 7,500 275.00
2012-05-29 2012-05-24 4 AMAG AMAG PHARMACEUTICALS INC.
Common Stock
P - Purchase 2,000 2,000 13.55 27,102 27,102
2012-05-25 2012-05-23 4 AMAG AMAG PHARMACEUTICALS INC.
Restricted Stock Unit
A - Award 3,800 3,800
2012-05-25 2012-05-23 4 AMAG AMAG PHARMACEUTICALS INC.
Stock Options
A - Award 7,600 7,600
2012-01-26 2012-01-25 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
A - Award 900,000 900,000
2009-04-02 3 OREX Orexigen Therapeutics, Inc.
No securities are beneficially owned
0
P
非衍生或衍生證券的公開市場或私下買入
S
非衍生或衍生證券的公開市場或私下賣出
A
公司向內部人員授予、獎勵或以其他方式獲取證券(例如股票期權)
C
衍生工具轉換
D
將證券賣出或轉讓回公司
F
使用從公司收到的證券的一部分來支付行使價或稅務負擔。
G
內部人士贈送或接收他人贈送公司股票
K
股權掉期和類似的避險交易
M
行使或轉換從公司獲得的衍生證券(例如期權)
V
內部人士透過Form 4自願報告的一筆交易
J
其他(附有交易描述的腳註)